Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06492174 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort
A Phase 3 study of In-Stent Restenosis, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 11
- Study locations
NCT06492174: Active Phase 3 study of In-Stent Restenosis, sponsored by Boston Scientific Corporation.
NCT06492174 is a Phase 3 study of In-Stent Restenosis that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 20 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06492174, a Phase 3 study of In-Stent Restenosis, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the AGENT IDE study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in diameter.
Primary Outcome
The primary endpoint is the 12-month Target Lesion Failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death
Conditions Studied
Interventions
- DEVICE AGENT DCB 40 mm
Study Locations (11)
New York
- Columbia University Medical Center - New York
- St. Francis Hospital - Roslyn
Arizona
- Carondelet Medical Group St. Mary's Hospital - Tucson
California
- Cedars Sinai Medical Center - Los Angeles
Georgia
- Emory University Hospital - Atlanta
Michigan
- Henry Ford Hospital - Detroit
Ohio
- Lindner Center for Research and Education at Christ Hospital - Cincinnati
Pennsylvania
- UPMC Pinnacle Health - Wormleysburg
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What the registry record for NCT06492174 still lists
NCT06492174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with In-Stent Restenosis appearing as the primary indexed condition, and to 1 intervention - of which AGENT DCB 40 mm is the first listed.
NCT06492174 lists 11 locations in 10 states (New York, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT06492174 about?
NCT06492174 is a clinical study titled "A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort". The purpose of the AGENT IDE study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in di...
What is the current status of trial NCT06492174?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2024-10-07. Estimated completion is 2027-12.
What conditions does trial NCT06492174 study?
This clinical trial studies the following conditions: In-Stent Restenosis.
What interventions are being tested in trial NCT06492174?
The interventions under investigation include: AGENT DCB 40 mm (DEVICE).
Who is sponsoring clinical trial NCT06492174?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06492174 being conducted?
This trial has 11 study locations across Arizona, California, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for In-Stent Restenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06492174's enrollment target sits among peer trials
20 1956th of 2000 higher than 32 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI